Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 131-139

  Jacobsen, Wolfgang ^a   Kirchner, Gabriele ^b   Hallensleben, Katrin ^b   Mancinelli, Laviero ^a   Deters, Michael ^c   Hackbarth, Ingelore ^b   Baner, Karen ^a   Benet, Leslie Z ^a   Sewing, Karl Friedrich ^b   Christians, Uwe ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MEVINOLIN; PRAVASTATIN; TROLEANDOMYCIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; SWINE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINE, SMALL; KETOCONAZOLE; LOVASTATIN; MALE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PRAVASTATIN; SWINE; TROLEANDOMYCIN;

EID: 0032825735     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Benet LZ, Wu CY, Hebert MF and Wacher VJ (1996) Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Control Rel 39:139-143.
2. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AI, Hesney M, Higgins J, Hurley DP, Langendørfer A, Nash DT, Pool JL and Schnaper H (1991) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Arch Intern Med 141:43-49.
3. Estabrook RW and Werringloer J (1978) The measurement of difference spectra: Application to the cytochromes of microsomes. Methods Enzymol 52:212-220.
4. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY and Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19:740-748.
5. Dimitroulakos J and Yeger H (1996) HMG-CoA reductase mediates the biologic effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein expressing cells. Nat Med 2:326-333.
6. Flint OP, Masters BA, Gregg RE and Durham SK (1997) HMG-CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low molecular weight proteins in neonatal rat muscle cell cultures. Toxicol Appl Pharmacol 145:99-110.
7. Gan LSL, Moseley MA, Koshla B, Augustijns PF, Bradshaw TP, Hnedren RW and Thakker DR (1996) CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporinee in Caco-2 cells: Interaction between the biochemical barriers to intestinal transport. Drug Metab Dispos 24:344-349.
8. Gorski JC, Hall SD, Jones DR, Vandenbranden M and Wrighton SA (1994) Regio-selective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
9. Greenspan MD, Yudkovitz JB, Alberts AW, Argenbright LS, Arison BH and Smith JL (1988) Metabolism of lovastatin by rat and human liver microsomes in vitro. Drug Metab Dispos 16:768-782.
10. Guengerich FP (1982) Microsomal enzymes involved in toxicology: Analysis and separation, in Principles and Methods of Toxicology (Hayes AW ed) pp 609-637, Raven Press, New York.
11. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed (Ortiz de Montellano PR ed) pp 473-535, Plenum Press, New York.
12. Henwood JM and Heel RC (1988) Lovastatin: A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs 36:429-454.
13. Hunter J and Hirst BH (1997) Intestinal secretion of drugs: The role of P-glycoprotein and related drug efflux systems in limiting oral absorption. Adv Drug DeIw Rev 25:129-157.
14. Hsu I, Spinler SA and Johnson NE (1995) Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 29:743-759.
15. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF and Christians U (1999) Comparison of cytochrome P450-dpendent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173-179.
16. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM and Lie KI (1995) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540.
17. Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Tkahagi H and Tanaka M (1993) Biotransformation of pravastatin sodium (I): Mechanism of enzymic transformation of epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 192:597-602.
18. Kolars JC, Lown KS, Schmiedlin-Ren P, Gosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
19. Lampen A, Christians U, Bader A, Hackbarth I and Sewing KF (1996) Drug interactions and interindividual variability of cyclosporine metabolism in the small intestine. Pharmacology 52:159-168.
20. Lampen A, Christians U, Guengerich FP, Watkins P, Kolars JC, Bader A, Dralle H, Hackbarth I and Sewing KF (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 23:1315-1324.
21. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ and Watkins PB (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporinee. Clin Pharmacol Ther 62:248-260.
22. MAAS Investigators (1994) Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Ann Intern Med 344:633-638.
23. Neuvonen PJ and Jalava MD (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61.
24. Obach RS (1997) Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
25. Ochs HR, Greenblatt DJ, Eichelkraut W, Bakker C, Göbel R and Hahn N (1987) Hepatic vs. gastrointestinal extraction of oral midazolam and flurazepam. J Pharmacol Exp Ther 243:852-856.
26. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Graidy P, Krekler M, Mangold B and Christians U (1997) Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinee-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 62:311-321.
27. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
28. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
29. Quion JAV and Jones PH (1994) Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 27:94-103.
30. Porteous JW, Furneaux HM, Pearson FK, Lake CM and Morison A (1979) Poly adenosine diphosphate ribose synthetase activity in nuclei of dividing but differentiating intestinal epithelial cells. Biochem J 180:455-463.
31. Pinkus LM (1981) Separation and use of enterocytes, in Methods in Enzymology (Jakoby WB ed) pp 154-162, Academic Press, New York.
32. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
33. Tobert JA (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318:48.
34. Triscari J, O'Donnell D, Zinny M and Pan HY (1995) Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 35:142-144.
35. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP and Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:355-361.
36. Vyas KP, Kari PH, Pitzenberger SM, Halpin RA, Ramjit HG, Arison B, Murphy JS, Hoffman WF, Schwartz MS, Ulm EH and Duggan DE (1990a) Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in rat and mouse. Drug Metab Dispos 18:203-211.
37. Vyas KP, Kari PH, Prakash SR and Duggan SR (1990b) Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation. Drug Metab Dispos 18: 218-222.
38. Vyas KP, Kari PH, Wang RW and Lu AYH (1990) Biotransformation of lovastatin-III. Effect of cimetidine and famotidine on in vitro metabolism by rat and human liver microsomes. Biochem Pharmacol 39:67-73.
39. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY and Wacher VJ (1995) Differentiation of absorption, first pass gut and hepatic metabolism in man: Studies with cyclosporinee. Clin Pharmacol Ther 58:492-497.